Genomic company ArcherDX Inc said on Tuesday that it has entered into a strategic collaboration to develop assays to support multiple planned Phase 3 clinical trials for AstraZeneca's targeted immuno-oncology therapeutics for early-stage non-small cell lung cancer therapies.
Pursuant to the agreement, ArcherDX will perform Whole Exome Sequencing (WES) of resected non-small cell lung cancer (NSCLC) patient samples and generate patient-specific circulating tumour DNA (ctDNA) assays.
In conjunction with the partnership, ArcherDX plans to leverage the PCM assays to develop companion diagnostics (CDx) for AstraZeneca's associated therapies as well as seek global regulatory approval if the Phase 3 clinical trials are completed successfully.
ArcherDX's Personalized Cancer Monitoring (PCM) development programme, which applies its Anchored Multiplex PCR (AMP) technology to accurately detect exceedingly low levels of cancer-derived DNA from patient blood, is supported by Professor Charles Swanton of UCL and the Francis Crick Institute as part of the Cancer Research UK-funded UCL-sponsored TRACERx study.
The master collaboration agreement also allows for expansion into additional disease indications and therapeutic categories.
Medivir and Vetbiolix report positive results from VBX-1000 Proof-of-Concept clinical study
Norgine submits first marketing authorisation application submissions for approval of eflornithine
Innovent Biologics names new Oncology CMO
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Precision Epigenomics partners with TruDiagnostic
Portage Biotech expands evaluation of strategic alternatives
Stamford Pharmaceuticals starts locally advanced basal cell carcinoma (laBCC) trial of SP-002
QST selects RayStation for advanced carbon ion therapy
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
ELIAS Animal Health names new chief revenue officer
Innate Pharma reports preclinical efficacy of IPH45
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
enGene Holdings names new senior vice president, Urologic Oncology and Clinical Development